AlkermesALKS
Market Cap: $4.55B
About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Employees: 2,100
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
133% more call options, than puts
Call options by funds: $5.06M | Put options by funds: $2.17M
17% more repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 110
0.67% more ownership
Funds ownership: 105.27% [Q1] → 105.94% (+0.67%) [Q2]
4% less funds holding
Funds holding: 331 [Q1] → 318 (-13) [Q2]
9% less capital invested
Capital invested by funds: $4.76B [Q1] → $4.32B (-$440M) [Q2]
23% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 57
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Cantor Fitzgerald Charles Duncan 47% 1-year accuracy 32 / 68 met price target | 79%upside $48 | Overweight Reiterated | 25 Jul 2024 |
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target | 19%upside $32 | Neutral Maintained | 25 Jul 2024 |
Baird Joel Beatty 51% 1-year accuracy 18 / 35 met price target | 41%upside $38 | Outperform Maintained | 25 Jul 2024 |
HC Wainwright & Co. Douglas Tsao 50% 1-year accuracy 70 / 139 met price target | 38%upside $37 | Neutral Maintained | 25 Jul 2024 |
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target | 15%upside $31 | Neutral Maintained | 15 Jul 2024 |
Financial journalist opinion
Based on 8 articles about ALKS published over the past 30 days